Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
04:05pm, Thursday, 09'th May 2024
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven'
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
02:38pm, Wednesday, 01'st May 2024
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treat
These Biotechs and IPOs Inspire Big Insider Buying
08:15am, Sunday, 28'th Apr 2024
As tech giants and other sector leaders report their most recent quarterly results, one might expect notable insider purchases to be scarce.
3 Biotech Stocks to Buy on the Dip: April 2024
06:00am, Friday, 26'th Apr 2024
If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlyin
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:05pm, Monday, 22'nd Apr 2024
NEW HAVEN, Conn. , April 22, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
06:00am, Thursday, 18'th Apr 2024
NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
04:05pm, Wednesday, 17'th Apr 2024
NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechani
How Biohaven's experimental obesity drug could prevent muscle loss
06:19pm, Monday, 25'th Mar 2024
Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
04:05pm, Thursday, 29'th Feb 2024
Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, ep
Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
12:48pm, Wednesday, 28'th Feb 2024
Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, s
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
05:31pm, Thursday, 25'th Jan 2024
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
06:00am, Thursday, 25'th Jan 2024
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzh
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
